Neurobiology and Physiology of the Endocannabinoid System
- 1st Edition - June 2, 2023
- Editors: Vinood B. Patel, Victor R Preedy, Colin R Martin
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 0 8 7 7 - 1
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 0 8 7 8 - 8
Neurobiology and Physiology of the Endocannabinoid System offers readers a comprehensive reference on the neurobiology of this system and the use of cannabimimetic compounds to ind… Read more

Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteNeurobiology and Physiology of the Endocannabinoid System offers readers a comprehensive reference on the neurobiology of this system and the use of cannabimimetic compounds to induce neurological changes and confer symptom relief. With sections on both natural and synthetic compounds, the book's broad coverage allows readers to learn about their use with multiple conditions, as well as the working biology of the endocannabinoid system, its receptors and its ligands. This volume provides a platform for research on the effects of this system and its modulation in brain function and neurological dysfunction.
- Summarizes research on the working neurobiology of the endocannabinoid system
- Contains chapter abstracts, key facts, a dictionary and a summary
- Covers both natural cannabinoids and synthetic or exogenous cannabimimetics
- Includes conditions like headache, anxiety, stress and neuroinflammation
- Discusses system modulation in the context of pain, traumatic brain injury and obesity
Researchers in neuroscience and the biomedical sciences, behavioral neuroscientists
- Cover
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Preface
- Part I: Setting the scene and introductory chapters
- Chapter 1: Distribution of the endocannabinoid system: Linking signaling and development
- Abstract
- Introduction
- Main text
- Prelude to neurodevelopment: Embryo implantation and placental function
- ECS and the phases of neurodevelopment
- Applications to other areas
- Mini-dictionary of terms
- Key facts of ECS impact on neurodevelopment
- Summary points
- References
- Chapter 2: The endocannabinoid system, immunomodulation, and LPS-induced inflammation
- Abstract
- Introduction
- Overview of the endocannabinoid system
- Expression of CB1, CB2, and other putative GPCR cannabinoid receptors by leukocytes and endothelial cells
- Expression of TRPs and PPARs by leukocytes and endothelial cells
- Modulation of endocannabinoids by inflammation and endotoxin
- Modulation of cannabinoid receptor expression by inflammation and endotoxin
- Links between signaling pathways engaged by cannabinoids and inflammatory agonists (Fig. 1)
- In vitro effects of endocannabinoids on activation of immune and endothelial cells (Table 1; Fig. 2)
- In vitro effects of phytocannabinoids on activation of immune and endothelial cells (Table 2; Fig. 2)
- In vivo effects of endocannabinoids on inflammation and endotoxemia (Table 3; Fig. 2)
- In vivo effects of phytocannabinoids on inflammation and endotoxemia (Table 4; Fig. 2)
- Applications to other areas
- Key facts
- Mini-dictionary of terms
- Summary points
- References
- Chapter 3: Physiology of the endocannabinoid system: Imaging and the use of positron emission tomography (PET)
- Abstract
- Introduction
- Future directions
- Applications to other areas
- Conclusions
- Minidictionary of terms
- Key facts of physiology of the endocannabinoid system: Imaging and the use of positron emission tomography (PET)
- Summary points
- References
- Chapter 4: The endocannabinoid system and aging
- Abstract
- Introduction
- Applications to other areas
- Minidictionary of terms
- Key facts of the endocannabinoid system and aging
- Summary points
- References
- Chapter 5: The endocannabinoid system and posttraumatic stress disorder (PTSD): A new narrative
- Abstract
- Introduction
- Association between PTSD and endocannabinoid biomarkers
- Relationship between human and animal models
- Relationship between fear conditioning and endocannabinoids in PTSD
- Relationship between endocannabinoid genetics and PTSD
- Effect of cannabinoids on PTSD symptomology
- Conclusions
- Application to other areas
- Mini-dictionary of terms
- Key facts of PTSD
- Summary points
- References
- Part II: Neurobiology of the endocannabinoid system
- Chapter 6: The protective effect of the endocannabinoid system in neurotoxin-induced damage to hippocampal neurons: a focus on light and electron microscopy
- Abstract
- Introduction
- Hyperexcitability and oxidative stress as the main factors leading to the development of temporal lobe epilepsy and Alzheimer’s disease
- Analysis of degenerative processes caused by the action of KA and Aβ
- Activation of the endocannabinoid system as a possible protector in the development of temporal lobe epilepsy and Alzheimer’s disease
- Applications to other areas
- Minidictionary of terms
- Key facts
- Summary points
- References
- Chapter 7: Endocannabinoid signaling at excitatory and inhibitory synapses
- Abstract
- Introduction
- Many components of the endocannabinoid signaling system are present at synapses
- Suppression of synaptic neurotransmitter release
- Long-term depression
- Long-term potentiation
- Local coordination between excitatory and inhibitory synapses in dendrites
- Applications to other areas
- Minidictionary of terms
- Key facts of endocannabinoids mediated synaptic plasticity
- Summary points
- References
- Chapter 8: The endocannabinoids and potassium channels—An updated narrative
- Abstract
- Introduction
- Discussion
- Applications to other areas
- Minidictionary of terms
- Key facts of potassium channels
- Summary points
- References
- Chapter 9: Insights into the endocannabinoid system from investigations of the development of social behavior in rodents of both sexes
- Abstract
- Introduction
- The endocannabinoid system
- The development of the endocannabinoid system in rats
- The development of social behavior in rats
- Neural mechanisms of social behavior
- Endocannabinoid system influences on social behavior
- Potential mechanisms underlying sex differences in ECS regulation of social behavior
- Applications to other areas
- Mini-dictionary of terms
- Key facts
- Summary points
- References
- Chapter 10: Exercise and Parkinson’s disease: Linking in the cannabinoid type 1 (CB1) and type 2 (CB2) and mu-opioid receptors
- Abstract
- Acknowledgment
- Introduction
- Physical activity as nonpharmacological alternatives for overcoming symptoms in PD
- Endocannabinoid system
- Opioidergic system
- Applications to other areas
- Mini-dictionary of terms
- Key facts of exercise and Parkinson’s disease
- Summary points
- References
- Chapter 11: Endocannabinoids and inhalant misuse: Neuropsychological aspects
- Abstract
- Introduction
- Brief review of inhalants and their uses
- Brain targets of inhalants
- Role of endocannabinoids in the cellular actions of toluene
- Toluene and the mPFC
- Toluene and the NAc
- Toluene and the BLA
- Effects of toluene and endocannabinoids on decision-making—Preclinical studies
- Applications to other areas
- Mini-dictionary of terms
- Key facts of endocannabinoids and inhalants
- Summary points
- References
- Chapter 12: Fatty acid amide hydrolase (FAAH) in substance use disorders: FAAH regulation and inhibition in cannabis, alcohol, nicotine, stimulant, and opioid use disorders
- Abstract
- Introduction
- FAAH can be genetically altered or pharmacologically inhibited
- Genetic variability of FAAH may impact risk for SUD
- How is FAAH activity affected in SUD?
- How does FAAH affect the SUD behavior of preference?
- FAAH might influence sensitivity to substances
- FAAH expression and effect of inhibition during substance withdrawal
- FAAH regulation and inhibition during substance abstinence or reinstatement
- Conclusion
- Applications to other areas
- Key facts of substance use disorders (SUDs)
- Mini-dictionary of terms
- Summary points
- References
- Chapter 13: Treatment of pain with dual fatty acid amide hydrolase (FAAH) enzyme and human soluble epoxide hydrolase (sEH) enzyme inhibitors: Interlinking the endocannabinoid system
- Abstract
- Introduction
- Current treatment options
- Soluble epoxide hydrolase (sEH) inhibitors
- Fatty acid amide hydrolase (FAAH) inhibitors
- Simultaneous inhibition of sEH and FAAH has synergistic effects on pain
- Designed multiple ligands
- Dual sEH/FAAH inhibitors
- Antinociceptive assessment of dual inhibitors
- Conclusion
- Applications to other areas
- Mini-dictionary of terms
- Key facts of chronic pain
- Summary points
- References
- Chapter 14: WWL70 targets the link between 2-arachidonoylglycerol and prostanoid pathways
- Abstract
- Introduction
- Enzymatic properties of ABHD6
- Therapeutic efficacy of WWL70
- Pharmacological characterization of WWL70
- Perspectives
- Summary points
- Key facts of ABHD6 inhibitor
- Applications to other areas
- Mini-dictionary of terms
- References
- Chapter 15: Endocannabinoid catabolic enzyme inhibitors and pain alleviation
- Abstract
- General overview of pain and current analgesics
- General overview of pain-related measures in preclinical research
- Targeting endocannabinoid catabolic enzyme inhibitors as candidate analgesics
- Preclinical pain matrix profiles for eCB catabolic enzyme inhibitors
- Additional considerations for eCB catabolic enzyme inhibitors and pain
- Applications to other areas
- Mini-dictionary of terms
- Key facts of endocannabinoid catabolic enzyme inhibitors and pain
- Summary points
- References
- Chapter 16: The endocannabinoid system in health and disease: Features in epilepsy
- Abstract
- Acknowledgments
- Endocannabinoid system
- Endocannabinoids in human epilepsy
- Effects of endocannabinoids in preclinical models of seizures, epileptogenesis, and epilepsy
- Endocannabinoids: Pro- or anticonvulsant effects
- Epilepsy and blood-brain barrier
- Endocannabinoid receptors, blood-brain barrier, and epilepsy
- Endocannabinoids and antiinflammatory effects in epilepsy
- Endocannabinoids and proinflammatory effects in epilepsy
- When do endocannabinoids induce harmful effects?
- Endocannabinoids may underly harmful effects through different mechanisms
- Endocannabinoids in epilepsy: To increase or not to increase
- Applications to other areas
- Mini-dictionary of terms
- Key facts of epilepsy
- Summary points
- References
- Chapter 17: The endocannabinoid system and autoimmune demyelination: A focus on multiple sclerosis
- Abstract
- Acknowledgments
- Introduction
- Autoimmune demyelination: Focus in multiple sclerosis
- The endocannabinoid system
- Role and therapeutic potential of (endo)cannabinoids in demyelination
- Applications to other areas
- Mini-dictionary terms
- Key facts of multiple sclerosis
- Summary points
- References
- Chapter 18: Endocannabinoid signaling in the lateral habenula regulates opioid addiction
- Abstract
- Acknowledgments
- Introduction
- The lateral habenula
- The endocannabinoid system (ECBS)
- Endocannabinoids in the lateral habenula
- Conclusion
- Applications to other areas
- Mini-dictionary of terms
- Key facts
- Summary points
- References
- Chapter 19: On the interplay among endocannabinoid, noradrenergic, and glucocorticoid systems: Evidence from aversive memory studies
- Abstract
- Introduction
- Noradrenergic modulation of fear memories and mechanisms underlying the endocannabinoid interplay
- Glucocorticoid effects on fear memories and mechanisms underlying the endocannabinoid interplay
- The cannabinoid-noradrenergic-glucocorticoid interplay in fear memories
- Conclusions
- Applications to other areas
- Mini-dictionary of terms
- Key facts of the noradrenergic system
- Key facts of the glucocorticoid system
- Summary points
- References
- Part III: Receptor biology and responses
- Chapter 20: Adenosine A2A-cannabinoid CB1 receptor heteromers in the brain: From trans-inhibition to trans-activation
- Abstract
- Introduction
- Evidence of A2AR and CB1R functional interactions
- Molecular confirmation of the existence of A2AR/CB1R heteromers
- Pharmacological consequences of A2AR/CB1R heteromerization
- Future perspectives and challenges in the field
- Applications to other areas
- Mini-dictionary of terms
- Key facts of A2A-CB1 receptor heteromers in the brain
- Summary points
- References
- Chapter 21: Role of hippocampal CB1 and CB2 receptors in fear memory consolidation, extinction, and reconsolidation
- Abstract
- Introduction
- The hippocampus and cannabinoid receptor location
- Effects of selective blockade or activation of hippocampal CB1 receptors in fear memory consolidation and acquisition
- Effects of selective blockade or activation of hippocampal CB2 receptors in fear memory consolidation
- Effects of unselective blockade or activation of hippocampal CB1 and CB2 receptors in memory consolidation and acquisition
- Effects of blockade or activation of hippocampal CB1 and CB2 receptors in fear memory reconsolidation
- Effects of blockade or activation of hippocampal CB1 and CB2 receptors in fear memory extinction
- Applications to other areas
- Concluding remarks
- Mini-dictionary of terms
- Key facts of memory and hippocampal function
- Summary points
- References
- Chapter 22: Possible use of beta-caryophyllene as an agent to facilitate the recovery from COVID-19-induced tissue and organ damage
- Abstract
- Introduction
- Cannabinoid receptor 2 signaling pathway
- Impact of COVID-19 on tissues/organs
- Possible utilization of BCP to facilitate the recovery from COVID-19-induced damage of tissues and organs
- Enhancing the effects of BCP
- Conclusion
- Applications to other areas
- Key facts of β-caryophyllene
- Mini-dictionary of terms
- Summary points
- References
- Further reading
- Chapter 23: CB1 agonism on mesolimbic and nigrostriatal dopaminergic neurotransmission
- Abstract
- Introduction
- Dopaminergic pathway: Role and regulation
- CB1 agonism in dopaminergic transmission
- Applications to other areas
- Mini-dictionary of terms
- Key facts of dopaminergic transmission
- Summary points
- References
- Chapter 24: Peripheral cannabinoid receptor 1 antagonists and impact on adipocytes
- Abstract
- Introduction
- Endocannabinoid system
- CB1 antagonist Rimonabant and adipose tissue function
- Peripheral CB1R antagonist and adipose tissue function
- Applications to other areas
- Mini-dictionary of terms
- Key facts of peripheral cannabinoid receptor 1 antagonists
- Summary points
- References
- Chapter 25: Plasma membrane localization of endocannabinoids system receptors
- Abstract
- Introduction
- Lipid rafts: Detergent-insoluble membrane domains
- A simplified method for the preparation of lipid rafts
- Plasma membrane localization of CB1 receptor
- Plasma membrane localization of CB2 receptor
- Different distribution of CB1 and CB2 receptor in the plasma membrane
- Key facts
- Mini-dictionary
- Summary points
- References
- Chapter 26: Applications to wound healing: Cannabinoid receptor 1 antagonism and collagen deposition
- Abstract
- Introduction
- Conclusions
- Applications to other areas
- Mini-dictionary of terms
- Key facts of wound healing
- Key facts of cannabinoids effect on wound healing
- Summary points
- References
- Chapter 27: The role of transient receptor potential vanilloid 1 (TRPV1), a modulator of the endocannabinoid system in anxiety, depression, and cocaine addiction
- Abstract
- Introduction
- TRPV1 expression within the central nervous system
- TRPV1 interactions with the endocannabinoid system
- The involvement of TRPV1 in anxiety and depression disorders
- Cocaine addiction and TRPV1
- Applications to other areas
- Mini-dictionary of terms
- Key facts of major depression disorder (MDD)
- Summary points
- References
- Chapter 28: Org27569, the allosteric modulators and the cannabinoid receptor 1 (CB1)
- Abstract
- Introduction
- Conclusion
- Applications to other areas
- Mini-dictionary of terms
- Key facts of cannabinoid receptors
- Key facts of allosteric modulators of cannabinoid receptors
- Summary points
- References
- Chapter 29: Naturally occurring delta-9-tetrahydrocannabinol derivatives and binding to CB1 and CB2 receptors: Linking in the endocannabinoid system
- Abstract
- Introduction
- History of cannabinoids
- Radioligand-binding assays
- Homogeneous time-resolved binding assays
- Delta-9-tetrahydrocannabinol and its main derived compounds
- Δ9-Tetrahidrocannabinolic acid (Δ9-THCA)
- Δ9-Tetrahydrocannabivarin (Δ9-THCV)
- Other Δ9-THC derivatives
- Applications to other areas
- Key facts
- Mini-dictionary of terms
- Summary points
- References
- Part IV: Profiles and behavior of selective endocannabinoids
- Chapter 30: New cannabinoid receptor type 1 and 2 agonists and applications to understanding the endocannabinoid system: A chemical approach
- Abstract
- Introduction
- WIN55,212-2 and the design of indole-based cannabinoid agonists
- Incorporation of new heterocycles in the search for new CB1R and CB2R agonists
- 3-Carboxamide derivatives: Quinolones and 2-pyridones as cannabinoid agonists
- Summary points
- Key factors
- Mini dictionary of terms
- References
- Chapter 31: Fatty acid amide hydrolase, anandamide, and neurological diseases
- Abstract
- Introduction
- Fatty acid amide hydrolase
- AEA and neurological disorders
- Clinical trials
- Applications to other area 1
- Applications to other area 2
- Mini-dictionary of terms
- Key facts of FAAH
- Key facts of AEA
- Summary points
- References
- Chapter 32: The endocannabinoid system in the immunobiology of dendritic cells
- Abstract
- Introduction
- The key components of endocannabinoid system
- Dendritic cells and their role in the immune system
- Endocannabinoid system in conventional dendritic cells
- Endocannabinoid system in plasmacytoid dendritic cells
- Conclusion
- Summary points
- References
- Further reading
- Chapter 33: Palmitoylethanolamide and other anandamide congeners in neuroinflammation-based disorders: Linking in the endocannabinoid system
- Abstract
- Introduction
- The “Good Actors” in Neuroinflammation
- Endocannabinoids in Neuroinflammation
- Endocannabinoids and Microglia
- Endocannabinoids and Astrocytes
- Endocannabinoids and Pro-inflammatory Mediators
- Endocannabinoids and Neurodegeneration
- Endocannabinoids and BBB
- Palmitoylethanolamide in Neuroinflammation-Based Disorders: Preclinical Trials
- Palmitoylethanolamide in Neuroinflammation-Based Disorders: Clinical Trials
- PEA Derivatives: The 2-Pentadecyl-2-oxazoline (PEA-OXA)
- Conclusions
- Application to Other Areas
- Mini-dictionary of Terms
- Key Facts of N-Acylethanolamine in Neuroinflammation
- Summary Points
- References
- Chapter 34: Endocannabinoid modulation of synaptic function and behavior in the dorsomedial hypothalamus
- Abstract
- Introduction
- Endocannabinoids and the DMH
- Synaptic effects of eCBs
- Appetite regulation and metabolism
- Stress, anxiety, and panic
- Sleep/arousal
- Cannabinoid interactions
- Applications
- Summary points
- Key facts
- Mini-dictionary of terms
- References
- Chapter 35: Key role of the endocannabinoid system with special emphasis in anandamide on the modulation of cardio-renal homeostasis
- Abstract
- Introduction
- Cardiovascular effects derived from pharmacological manipulation of the endocannabinoid system
- Endocannabinoid system management and its consequences on kidney functions
- Conclusion and prospects
- Application to other areas
- Mini-dictionary of terms
- Key facts of cardio-renal diseases
- Summary points
- References
- Chapter 36: The endocannabinoid system: Signaling and social motivation
- Abstract
- Introduction
- The endocannabinoid system (ECS)
- Cannabinoid receptors
- Social decision-making network (SDMN)
- Behavioral paradigms to assess sociability in rodents
- Endocannabinoids’s role on social reward and motivation
- Applications to other areas
- Mini-dictionary of terms
- Key facts of social motivation
- Summary points
- References
- Part V: Exogenous, synthetic other compounds linking in the endocannabinoid system
- Chapter 37: Safety and toxicology of the dietary cannabinoid β-caryophyllene
- Abstract
- Sesquiterpene: β-Caryophyllene
- Research strategy
- Safety and toxicology
- General toxicology evaluation
- Mutagenicity/genotoxicity studies
- Conclusion
- Key facts of β-caryophyllene
- Mini-dictionary of terms
- Summary points
- References
- Chapter 38: Synthetic cannabinoid receptor agonists: An overview
- Abstract
- Introduction
- Phytocannabinoid-like structures
- Indole-based structures—Historic development
- Alkyl chain variation
- Hydrophobic group modification
- Linker variation
- Indazole-based structures
- Azaindoles-based structures
- Miscellaneous structures
- Conclusions
- Applications to other areas
- Mini-dictionary of terms
- Key facts on legal regulation of synthetic cannabinoid receptor agonists
- Summary points
- References
- Part VI: Comparative studies in nonneurological systems
- Chapter 39: Nonneurological aspects of the endocannabinoid system: Nonalcoholic fatty liver disease
- Abstract
- Introduction
- Conclusion
- Applications to other areas
- Mini-dictionary of terms
- Key facts of NAFLD
- Summary points
- References
- Chapter 40: Components of the endocannabinoid system: Hepatic expression levels of the cannabinoid receptors and microRNAs
- Abstract
- Introduction
- What are the components of the endocannabinoid system?
- Cannabinoid receptors and microRNAs in all organs
- Expression states and relationships of cannabinoid receptors and microRNAs in the liver
- CBRs in liver diseases
- Mini-dictionary of terms
- Key facts of cannabinoid receptors
- Key facts of microRNA
- Key facts of liver disease
- Summary points
- References
- Chapter 41: Tumor growth and the endocannabinoid system: Investigating CB2 agonists
- Abstract
- Introduction
- Cannabinoids breast cancer in vivo preclinical studies
- Cannabinoids in clinical cancer studies
- Cannabinoids mechanisms of action in cancer
- Conclusion and limitations
- Applications to other areas
- Mini-dictionary of terms (5–15 terms) (A–Z order)
- Key facts of cannabinoids and tumor growth
- Summary points
- References
- Chapter 42: Linking endocannabinoid system, palmitoylethanolamide, and sarcopenia in view of therapeutic implications
- Abstract
- Introduction
- Sarcopenia
- The endocannabinoid system (ECS) in skeletal muscle tissue
- Palmitoylethanolamide (PEA)
- Nanoparticles for PEA delivery and for muscle cell targeting
- Applications to other areas
- Mini-dictionary of terms
- Key facts of PPARα
- Summary points
- References
- Part VII: Resources
- Chapter 43: Recommended resources for studying and investigating the neurobiology and physiology of the endocannabinoid system
- Abstract
- Acknowledgments
- Introduction
- Resources
- Other resources
- References
- Index
- No. of pages: 600
- Language: English
- Edition: 1
- Published: June 2, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780323908771
- eBook ISBN: 9780323908788
VP
Vinood B. Patel
Dr. Patel is a Reader at the University of Westminster. After completing his PhD at King’s College London, he continued his research experience by undertaking his post-doctoral studies in the laboratory of Professor Cunningham in the Department of Biochemistry at the Wake Forest University School of Medicine, (Winston-Salem, NC, USA). This extensive project involved investigating mechanisms of hepatic mitochondrial ribosome dysfunction in alcoholic liver disease (ALD) using biophysical and proteomic techniques. These studies have led to new avenues in determining the pathology of ALD. His teaching areas at both post-graduate and undergraduate levels include clinical biochemistry, investigative pathology and laboratory investigation.
Affiliations and expertise
Reader, University of Westminster, London, UKVP
Victor R Preedy
Victor R. Preedy BSc, PhD, DSc, FRSB, FRSPH, FRSC, FRCPath graduated with an Honours Degree in Biology and Physiology with Pharmacology. After gaining his University of London PhD, he received his Membership of the Royal College of Pathologists. He was later awarded his second doctorate (DSc), for his contribution to protein metabolism in health and disease. He is Professor of Clinical Biochemistry (Hon) at King’s College Hospital and Emeritus Professor of Nutritional Biochemistry at King’s College London. He has Honorary Professorships at the University of Hull, and the University of Suffolk. Professor Preedy was the Founding Director and then long-term Director of the Genomics Centre at King’s College London from 2006 to 2020. Professor Preedy has been awarded fellowships of the Royal Society of Biology, the Royal College of Pathologists, the Royal Society for the Promotion of Health, the Royal Institute of Public Health, the Royal Society for Public Health, the Royal Society of Chemistry and the Royal Society of Medicine. He carried out research when attached to the National Heart Hospital (part of Imperial College London), The School of Pharmacy (now part of University College London) and the MRC Centre at Northwick Park Hospital. He has collaborated with international research groups in Finland, Japan, Australia, USA, and Germany. To his credit, Professor Preedy has published over 750 articles, which includes peer-reviewed manuscripts based on original research, abstracts and symposium presentations, reviews and edited books.
Affiliations and expertise
Professor, Department of Clinical Biochemistry, King’s College Hospital, London, UK; Emeritus Professor, Faculty of Life Sciences and Medicine, King’s College London, UK Visiting Professor, University of Hull, UKCR
Colin R Martin
Colin R. Martin RN, BSc, MSc, PhD, MBA, YCAP, FHEA, C.Psychol, AFBPsS, C.Sci is Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director of the Institute of Health and Wellbeing at the University of Suffolk, UK. He is a Chartered Health Psychologist and a Chartered Scientist. He also trained in analytical biochemistry, this aspect reflecting the psychobiological focus of much of his research within mental health. He has published or has in press well over 300 research papers and book chapters. He is a keen book author and editor having written and/or edited more than 50 books. These outputs include the prophetic insight into the treatment of neurological disease, Handbook of Behavior, Food and Nutrition (2011), Nanomedicine and the Nervous System (2012), Oxidative Stress and Dietary Antioxidants in Neurological Disease (2020), Zika Virus Impact, Diagnosis, Control and Models (2021), Factors Affecting Neurodevelopment: Genetics, Neurology, Behavior and Diet (2021), Diagnosis and Treatment of Spinal Cord Injury (2022), The Neurobiology, Physiology, and Psychology of Pain (2022) and The Handbook of Lifespan Cognitive Behavioral Therapy: Childhood, Adolescence, Pregnancy, Adulthood, and Aging (2023). Professor Martin is particularly interested in all aspects of the relationship between underlying physiological substrates and behavior, particularly in how these relationships manifest in both acute and chronic psychiatric disorder. He has published original research germane to significant mental health disorders including the areas of schizophrenia, anxiety, depression, self-esteem, alcohol and drug dependency, high secure forensic mental health and personality disorder. He has a keen interest in the impact of postviral illness and is actively involved in clinical research post-Covid pandemic and in particular, the impact of Long Covid on psychological, neurological, physiological and social functioning. He is involved in collaborative International research with many European and Non-European countries.
Affiliations and expertise
Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director: Institute for Health and Wellbeing, University of Suffolk, Ipswich, UKRead Neurobiology and Physiology of the Endocannabinoid System on ScienceDirect